WASHINGTON—The ileal bile acid transporter inhibitors odevixibat and maralixibat resulted in improvements in liver disease markers and symptoms and were well tolerated overall during several pediatric trials presented at The Liver Meeting 2022. The following is a summary of several studies.
Odevixibat Contributes to Enhanced Native Liver Survival in PFIC
Odevixibat (Bylvay, Albireo) may improve native liver survival in patients with progressive familial intrahepatic cholestasis